BACKGROUND AND PURPOSE: Patient-derived tumor 3D multicellular cultures are a novel non-small cell lung cancer (NSCLC) model for studying tumor biology and precision medicine, which recapitulates tumor morphology and gene expression profile. However, practical application is challenged by issues such as low establishment rates, long-term production difficulties, and the absence of immune microenvironment components. To address these issues, this study aimed to evaluate the efficacy of a novel method for generating free-floating patient-derived organotypic tumor spheroids (PDOTS) using a stimuli-responsive extracellular matrix (ECM)-mimicking gel. EXPERIMENTAL APPROACH: Free-floating PDOTS were established from 18 NSCLC tumors and characterized by their morphology, marker expression, and extracellular matrix composition. Cell composition in PDOTS and their parental tumors was analyzed by flow cytometry, while RT-PCR was used to assess the expression of genes encoding signaling molecules. Finally, drug response and the expression of drug resistance genes were evaluated in the NSCLC PDOTS. FINDINGS/RESULTS: The PDOTS were successfully generated with a success rate exceeding 90%, forming spheroids within one week. These PDOTS preserved the parental tumor's morphology and included stromal and immune cells. Notably, 58% of the PDOTS maintained cytokine and growth factor expression profiles closely mimicked those of the original tumors. Furthermore, the PDOTS demonstrated varied responses to anticancer drugs, potentially influenced by differential expression of drug resistance-associated genes. CONCLUSION AND IMPLICATIONS: The high establishment rate and rapid production timeline of free-floating PDOTS using a stimuli-responsive ECM-mimicking gel make this approach a promising tool for advancing cancer biology research and evaluating therapeutic strategies with greater accuracy.
Free-floating patient-derived organotypic tumor spheroids (PDOTS) from non-small cell lung cancer (NSCLC) tumors: a versatile tool for personalized testing of chemotherapeutic drugs.
来自非小细胞肺癌 (NSCLC) 肿瘤的游离患者来源的器官型肿瘤球体 (PDOTS):一种用于个性化化疗药物测试的多功能工具。
阅读:6
作者:
| 期刊: | Research in Pharmaceutical Sciences | 影响因子: | 2.100 |
| 时间: | 2025 | 起止号: | 2025 Oct 20; 20(5):651-666 |
| doi: | 10.4103/RPS.RPS_233_24 | 靶点: | CLC |
| 研究方向: | 细胞生物学、肿瘤 | 疾病类型: | 肺癌 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
